SURVYR

KARD

Kardigan, Inc.
$13.60
+$0.97 (7.68%)Oct 27 close
Healthcare CompareTechnicals
1M3M6M1Y2Y
-44%-28%-11%+6%+23%Jun 18Oct 27Aug 2252w high $27.0052w low $12.23
KARDSPY
Wall St. Highest PT $46.00 (+238.2%) Wall St. Avg PT $39.50 (+190.4%)
$13$25$38$50$63POC $21Hi $46Avg $40
Underwater Drawdown %Max DD -51.2%Current -47.5%
0.0%-51.2%
Relative Strength vs SPY-41.5% vs SPYUnderperforming
+52%0%-52%
1W
+$0.09 (0.67%)
1M
−$1.19 (8.05%)
3M
−$7.39 (35.21%)
6M
–
YTD
–
1Y
–

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Strong Buy
6 analysts · mean score 1.14
1 = Strong Buy · 5 = Sell
Wall Street consensus
Analyst price targets
Current price$13.60
Average target$39.50
+$25.90 (+190.4%) upsideaverage target vs current price
CurrentAverageMedian
Low$25.00
Median$39.50
High$46.00
12-month Wall Street target range
Recent analyst rating changes · 8
Initiated
2026-10-22 · Baird started covering KARD at Outperform
Initiated
2026-10-16 · William Blair started covering KARD at Outperform
Initiated
2026-10-12 · UBS started covering KARD at Buy
Reiterated
2026-08-25 · JP Morgan reiterated Overweight on KARD
Initiated
2026-07-13 · TD Cowen started covering KARD at Buy
Initiated
2026-07-13 · Leerink Partners started covering KARD at Outperform
All analyst rating changes ›

Third-party ratings, not SURVYR.'s views.

Key stats & company

Market value$1.2B
P/E (next 12 months, estimated)-3.1
52-week range$12.23 – $27.00
Dividend yieldNo dividend
Analyst consensusStrong Buy (6)
Average analyst price target$39.50 (+190%)

What they do

Kardigan, Inc. operates as a biopharmaceutical company focused on developing medicines for cardiovascular diseases. The company develops and provides a portfolio of medicines that target the underlying pathophysiology of cardiovascular diseases, including primary and secondary cardiomyopathies leading to heart failure. It utilizes a proprietary research and development platform that integrates AI-based tools, real-world clinical data.

Healthcare · Biotechnology
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

No sector grades for KARD yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
 SURVYR. Long Book
Not in the current book

Earnings & events

KARD earningsNext report in 12 days
Next report
Mon Nov 9, 2026Before the open
EPS consensus-$1.08 range -$2.34–-$0.69
Revenue consensus$0 5 analysts
Last 1 quarters · EPS vs estimate
Aug 11, 2026-$2.89est -$0.64−350.6%Below estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · refreshed 2026-10-24 03:05:09 ET
26-08-2.890.00
EstimateActual (beat)Actual (miss)

Quarterly revenue

QuarterRevenueYoY
2026-06-30$0–
2026-03-31$0–
2025-06-30$0–
2025-03-31$0–

News & catalysts

More news
Kardigan And 2 Founder Run Stocks To Own
Simply Wall St. · Oct 20
Kardigan Announces Appointment of Kristin Reinke to its Board of Directors
Business Wire · Sep 30
Kardigan to Present at Two September Investor Conferences
Business Wire · Sep 02
Citi scoops up rewards fintech Kard
Banking Dive · Aug 17
Citigroup's Kard Acquisition Deal: A New Growth Engine for U.S. Cards?
Zacks · Aug 14
Rating changes
Initiated
2026-10-22 · Baird started covering KARD at Outperform
Initiated
2026-10-16 · William Blair started covering KARD at Outperform
Initiated
2026-10-12 · UBS started covering KARD at Buy
Reiterated
2026-08-25 · JP Morgan reiterated Overweight on KARD
Initiated
2026-07-13 · TD Cowen started covering KARD at Buy
Initiated
2026-07-13 · Leerink Partners started covering KARD at Outperform

Third-party analyst actions, not SURVYR.'s views. All rating changes

Insider trades
None
None · None
Sell
–

Stats refreshed 2026-10-24 03:05:09 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026